Genetic Variant Associated With Alzheimer's Protection Works Through Brain Barrier Maintenance

Researchers identified that the APOEε2 genetic variant, which offers protection against Alzheimer's disease, strengthens the blood-brain barrier by improving pericyte function and promoting efficient lipid processing in these critical support cells. Using human cell models and mouse studies, scientists found that APOE2 pericytes maintained better barrier integrity, resisted cellular aging, and reduced harmful protein accumulation compared to other APOE variants. The findings suggest that enhancing pericyte lipid metabolism could be a therapeutic target for preventing neurodegenerative diseases associated with a leaky blood-brain barrier.

The blood-brain barrier functions as a gatekeeper, blocking harmful substances from reaching brain tissue while allowing necessary nutrients through. Over time, this protective wall deteriorates, allowing damaging molecules to leak into the brain and trigger inflammation. Pericytes—specialized cells wrapped around brain blood vessels—play a crucial role in maintaining this barrier's structural integrity. When these cells weaken, the barrier fails, potentially setting the stage for neurodegenerative disease development.

Researchers compared three versions of the APOE gene by creating human brain cell cultures with each variant. The APOE2 version produced pericytes that processed lipids more efficiently, resisted aging better, and prevented buildup of amyloid-beta, a toxic protein linked to neurodegeneration. Treating APOE3 and APOE4 pericytes with synthetic APOE2 protein restored their function, suggesting the mechanism could be therapeutically targeted.